Related Experiment Video
Updated: Sep 16, 2025
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
Contemporary perspectives in cerebral amyloid angiopathy
Amina Sellimi1,2, Julian Schwartze3, Fiona Humphries3
1Department of Translational Neuroscience and Stroke, Stroke Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Insights
Cerebral amyloid angiopathy (CAA), a cause of stroke and cognitive decline from amyloid-β buildup, presents complex clinical challenges. Understanding its dynamic nature and inflammation
Area of Science:
- Neurology and Neurobiology
- Vascular Dementia Research
- Amyloidosis Pathogenesis
Background:
- Cerebral amyloid angiopathy (CAA) is a primary cause of intracranial hemorrhage and cognitive decline due to amyloid-β deposition in cerebral vasculature.
- Current understanding of CAA pathogenesis and its diverse clinical manifestations remains incomplete, with no definitive treatments established.
- Managing CAA patients involves complexities arising from emerging anti-amyloid-β therapies and comorbidities like atrial fibrillation.
Purpose of the Study:
- To provide expert perspectives on cerebral amyloid angiopathy (CAA), from amyloid-β deposition to clinical outcomes.
- To explore the role of inflammation and the concept of iatrogenic CAA as a distinct entity.
- To examine current management challenges, future research directions, and potential therapeutic strategies for CAA.
Main Methods:
- Review and synthesis of current research and expert opinion on cerebral amyloid angiopathy (CAA).
- Analysis of emerging insights into CAA natural history, including dynamic disease progression.
- Discussion of novel diagnostic and therapeutic approaches, including biomarkers and anti-amyloid therapies.
Main Results:
- Recent findings suggest a dynamic, non-linear natural history of CAA with periods of activity and remission.
- Inflammation is identified as a key area for therapeutic investigation in CAA.
- Iatrogenic CAA presents a unique model for studying amyloid-β prion disease dynamics.
Conclusions:
- CAA management is complicated by evolving therapies and patient comorbidities, necessitating improved diagnostic tools.
- Future research should focus on limiting amyloid-β production, enhancing clearance, and targeting vascular remodeling and inflammation.
- A deeper understanding of CAA's complex pathophysiology is crucial for developing effective treatments.
Introduction:
Cerebral amyloid angiopathy (CAA) is a leading cause of intracranial hemorrhage and cognitive decline, resulting from amyloid-β accumulation in the walls of small cortical and leptomeningeal arterioles. While models of pathogenesis exist, the mechanisms leading to the diverse clinical manifestations of CAA remain largely unknown. There are no proven treatments, but a few clinical trials are ongoing. Meanwhile, emerging anti-amyloid-β therapies and managing patients with comorbidities including atrial fibrillation complicate clinical-practice in peopel with CAA.
Areas Covered:
Herein, the authors provide their perspectives on CAA from initial amyloid-β deposition to clinical disease manifestations. They also discuss the emergence of iatrogenic CAA and the potential role of inflammation across CAA, questioning the concept of a single entity. Finally, the authors examine management challenges, future research horizons, and treatment directions.
Expert Opinion:
Recent insights challenge the traditional view of a linearly progressive disease, suggesting a dynamic natural history with periods of high activity and remission. Inflammation is a topic of active investigation, with potential therapeutic relevance. Challenges remain, including the need for improved neuroimaging and fluid biomarkers for noninvasive early diagnosis. Iatrogenic CAA is a recently described amyloid-β prion disease in younger people, with known Aβ innoculation and exposure times, providing a potential 'pure' model of CAA. Research into limiting Aβ production, improving perivascular clearance, or modifying vascular remodeling and inflammation may guide novel therapeutics.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:22Alzheimer's Disease: Treatment
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies